Semaglutide, Tirzepatide, Retatrutide, Mazdutide, Survodutide and more
EhBuddy Research-Grade Survodutide
Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist in Phase 3 trials for obesity and NASH. Research data from the LIGHT UP trials demonstrates substantial body weight reduction along with significant improvements in liver histology — making it one of the most promising compounds in NASH research alongside metabolic syndrome.
Reconstitution: Bacteriostatic Water (BAC Water) or Sterile Water required.
FOR RESEARCH USE ONLY (RUO). Not approved for human or veterinary use. Intended for in vitro and laboratory research only. EhBuddy Peptides assumes no liability for misuse.
EhBuddy Retatrutide Injection Pen (Adjustable Dosage) — Available in 10mg Prefilled Pen, 15mg Prefilled Pen, 20mg Prefilled Pen, 30mg Prefilled Pen, 40mg Prefilled Pen Adjustable dosage – 2.5mg / 5mg / 10mg
EhBuddy's Retatrutide Prefilled Injection Pen delivers research-grade Retatrutide in a convenient, adjustable-dose pen format. Available in multiple pre-filled concentrations with adjustable dosing mechanisms (2.5mg / 5mg / 10mg settings) — providing the most precise and convenient delivery system for Retatrutide research protocols.
FOR RESEARCH USE ONLY (RUO). Not approved for human or veterinary use. Intended for in vitro and laboratory research only.

You must be 18 or 19 years of age depending on the age of majority in your province and a licensed research professional.
All products — including research peptides and research compounds — are sold strictly for laboratory and scientific research purposes only. Not for human or veterinary consumption. No dosing instructions are provided.
We adhere to all provincial and federal laws in Canada governing Research Only Chemical sales.
By clicking "I Agree" you confirm you have read and accepted the Terms and Conditions above.